<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02046746</url>
  </required_header>
  <id_info>
    <org_study_id>DA03</org_study_id>
    <nct_id>NCT02046746</nct_id>
  </id_info>
  <brief_title>The Effect of a Renal Specific Oral Nutritional Supplement on Nutritional Status</brief_title>
  <official_title>The Effect of a Renal Specific Oral Nutritional Supplement on Nutritional Status and Other Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate if a renal specific oral nutrition supplement (ONS) aids
      in maintaining nutritional status.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Serum Albumin</measure>
    <time_frame>Change from Month 0 to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Global Assessment</measure>
    <time_frame>Change from Month 0 to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Intake Compliance</measure>
    <time_frame>Change from Month 0 to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Grip Strength</measure>
    <time_frame>Change from Month 0 to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>Change from Month 0 to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Change from Month 0 to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Change from Month 0 to Month 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Oral Nutritional Supplement (ONS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-2 serving per day of a renal specific oral nutritional supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Nutritional Supplement (ONS)</intervention_name>
    <description>renal specific commercially available ONS</description>
    <arm_group_label>Oral Nutritional Supplement (ONS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;18 years of age

          2. Diagnosed with Chronic Kidney Disease (CKD); Stages 3b to 5

          3. eGFR ≤ 45 and ≥ 10 ml/min/1.73m2

          4. Male or non-pregnant female at least six weeks postpartum and non-lactating

          5. Subject with CKD is either: not diagnosed with Type 2 Diabetes Mellitus (T2DM) OR
             diagnosed with T2DM and had no changes in glycemic medication (dose or type) for at
             least 2 months

          6. Serum albumin ≥ 3.0g/dl

          7. BMI ≤ 27 kg/m2

          8. If T2DM, subject has A1c level ≤ 9.0%

          9. Not scheduled or expected to receive dialysis in the next 18 months

         10. Life expectancy &gt;18 months

        Exclusion Criteria:

          1. Type 1 diabetes

          2. Subjective Global Assessment = 1 to 3

          3. Intravenous albumin treatment within the last 6 months.

          4. Overt symptomatic peripheral neuropathy, retinopathy, or autonomic neuropathy.

          5. Poorly controlled chronic hypertension &gt;200/100 or hypotension &lt;90/60 defined by The
             Joint National Committee 7 (JNC 7).

          6. Major surgery, inpatient or outpatient, requiring &gt;7 days of hospitalization in the
             last 3 weeks prior to screening visit, or is having major elective surgery requiring
             &gt;7 days of hospitalization throughout the course of the entire study.

          7. Chronic/contagious infectious disease, clotting or bleeding disorder, active
             malignancy or impaired liver function

          8. Missing, or has had an amputation of, a limb.

          9. Significant cardiovascular event  ≤ 6 months; or stated history of congestive heart
             failure

         10. Obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel
             syndrome or other forms of gastrointestinal disease such as gastroparesis,
             pancreatitis, hepatitis, jaundice, celiac disease, intestinal dysmotility and
             ischemic colitis.

         11. Current diagnosis or history of severe dementia or delirium, eating disorder, history
             of significant neurological or psychiatric disorder, alcoholism, substance abuse

         12. Medications/dietary supplements/herbals or substances that could modulate glucose
             metabolism, or are considered anabolic, or can reduce fat mass, including but not
             limited to protein/amino acid supplements, or modified amino acid supplements such as
             keto acids, growth hormone, dronabinol, marijuana, calcium
             beta-hydroxyl-beta-methylbutyrate, high dose fish oil supplements (&gt;0.5 g omega-3/d)
             or vitamin D (&gt;400IU/d),

         13. Allergic or intolerant to any ingredient found in the study product.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen Kelly, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen DeLuca, MS, RD</last_name>
    <phone>614-624-5455</phone>
    <email>kristen.deluca@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bobbie Swearengin, RN</last_name>
    <phone>614-624-7182</phone>
    <email>bobbie.swearengin@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital (KMUH)</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Shang-Jyh Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 24, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
